MedPath

Dose Esmolol Infusion Have an Adjuvant Effect to TAP Block for Pain Control in Laparoscopic Cholecystectomy.

Phase 4
Completed
Conditions
Postoperative Pain
Interventions
Registration Number
NCT04752111
Lead Sponsor
Benha University
Brief Summary

Pain after laparoscopy differs considerably from that seen after laparotomy. Laparotomy results mainly in parietal pain (abdominal wall), where as Pain in laparoscopy results from stretching of the intra-abdominal cavity, peritoneal inflammation, and diaphragmatic irritation caused by residual carbon-dioxide in the peritoneal cavity. The transverse abdominis plane (TAP) block is a peripheral nerve block designed to anesthetize the nerves supplying the anterior abdominal wall (T6 to L1). While esmolol is an ultra-short acting intravenous β-blocker having a rapid onset and offset effect. It provides an unprecedented level of tolerability and safety in the perioperative setting. When used as an adjunct, it has been shown to improve the postoperative recovery by reducing postoperative pain intensity and intraoperative anesthetic and opioid requirements and preventing opioid-induced hyperalgesia . The mechanism of this synergistic effect is uncertain, but both pharmacokinetic and pharmacodynamics interactions with anesthetic drugs have been proposed.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  1. ASA grade I/II patients undergoing laparoscopic cholecystectomy .
  2. Age group of 18 -60 years.
  3. Patients giving valid informed consent.
Exclusion Criteria
  1. Patient refusal
  2. Patients belonging to ASA grade III and grade IV .
  3. Coagulation disorders.
  4. Patients with known allergy to one of the used drugs.
  5. Extreme obesity (BMI >35)
  6. Patients with cardiac, pulmonary, hepatic or renal disorders
  7. Pregnancy
  8. Drug abusers

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Group E (esmolol infusion)Esmolol10 minutes before induction of anesthesia the patients will receive a loading dose of injection esmolol 0.5 mg/kg in 30 ml isotonic saline in the IV line, followed by an IV infusion of esmolol 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side .
Group T (TAP block)Esmolol10 minutes before induction of anesthesia the patients will receive a loading dose of injection 30 ml isotonic saline in the iv line, followed by an IV infusion of saline at a rate of 0.05 mg/kg/min till the completion of surgery After induction of anesthesia and before starting the surgery, patients will receive bilateral in-plane ultrasound guided transversus abdominis plane block with 40 ml of bupivacaine 0. 25% after induction of anesthesia 20 ml in each side.
Primary Outcome Measures
NameTimeMethod
pain rescue-analgesia consumption24 hours postoperative

. If pain score exceed 3, rescue analgesia 5 mg bolus of morphine will be administered intravenous to achieve satisfactory pain control that can be repeated every 4-6 hours.

Secondary Outcome Measures
NameTimeMethod
Postoperative nausea and vomiting24 hours postoperative

A three-point rating scale (1: no postoperative nausea and vomiting, 2: nausea without vomiting, 3: nausea with vomiting. Ondansetron 4 mg will be available if required.

Patient satisfaction24 hours postoperative

using a 5-point Likert scale (1 was "very unsatisfied", 2- "unsatisfied", 3- "unsure", 4- "satisfied", and 5- "very satisfied").

Intraoperative hemodynamic data30 minutes after induction of anesthesia

mean arterial blood pressure and heart rate

Visual analogue pain scoreevery 0,2,4,6,12, up to 24 hours postoperative

scales from zero (no pain) to ten (unbearable pain)

Trial Locations

Locations (1)

Samar Rafik Mohamed Amin

🇪🇬

Benha, Qalubia, Egypt

© Copyright 2025. All Rights Reserved by MedPath